Elevated Methemoglobin Levels in a Patient Treated with Hydroxocobalamin After Suspected Cyanide Exposure
- PMID: 33011041
- DOI: 10.1016/j.jemermed.2020.07.008
Elevated Methemoglobin Levels in a Patient Treated with Hydroxocobalamin After Suspected Cyanide Exposure
Abstract
Background: Cyanide (CN) toxicity commonly occurs during enclosed-space fires. Historically, the first step in treating CN toxicity utilized amyl nitrite and sodium nitrite to induce methemoglobinemia, which can be dangerous in this population. Hydroxocobalamin (OHCob), which binds to CN to form the nontoxic metabolite cyanocobalamin, is now the first-line antidote for CN toxicity, and has the advantage of not inducing methemoglobinemia.
Case report: A 62-year-old man presented to the Emergency Department (ED) after a house fire. He was intubated for respiratory distress and hypoxia with an initial carboxyhemoglobin of 1.3%, methemoglobin 0.3%, and anion gap 19. Eleven hours after presentation, his serum lactic acid was 9 mmol/L. Given his continued deterioration, 14 h after arrival he received OHCob 5 g i.v. for presumed CN toxicity. Methemoglobin concentration 4 min prior to OHCob administration was 0.7%, and 2 h after administration was 4.2%. This subsequently increased to 14.3% (16 h after OHCob administration) and peaked at 16.3% (47 h after OHCob administration), at which time he was administered a dose of methylene blue 50 mg i.v., 60 h after ED arrival. His methemoglobin concentrations fluctuated until a consistent downward trend starting at 92 h from ED arrival. He continued to deteriorate and expired on hospital day 5 with a methemoglobin concentration of approximately 6.0%. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: CN toxicity requires immediate recognition and treatment. The antidote, OHCob, is believed to not induce methemoglobinemia. However, this potential side effect must be considered by emergency physicians when treating suspected CN toxicity, especially if the patient does not improve after antidotal therapy.
Keywords: cyanide; house fire; hydroxocobalamin; methemoglobinemia.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Elevated methemoglobin levels in patients treated with hydroxocobalamin: a case series and in-vitro analysis.Clin Toxicol (Phila). 2022 Sep;60(9):1012-1018. doi: 10.1080/15563650.2022.2072315. Epub 2022 May 12. Clin Toxicol (Phila). 2022. PMID: 35549585
-
Hydroxocobalamin is not associated with methemoglobinemia in patients with inhalation injury and suspected cyanide toxicity and a proposed algorithm for hydroxocobalamin administration.Burns. 2024 Sep;50(7):1746-1751. doi: 10.1016/j.burns.2024.04.007. Epub 2024 Apr 24. Burns. 2024. PMID: 38760187
-
Acquired methemoglobinemia after hydroxocobalamin administration in a patient with burns and inhalation injury.Clin Toxicol (Phila). 2018 May;56(5):370-372. doi: 10.1080/15563650.2017.1377838. Epub 2017 Oct 3. Clin Toxicol (Phila). 2018. PMID: 28969436
-
Antidotal treatment of cyanide poisoning.J Chin Med Assoc. 2003 Apr;66(4):193-203. J Chin Med Assoc. 2003. PMID: 12854870 Review.
-
Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning?Ann Emerg Med. 2007 Jun;49(6):806-13. doi: 10.1016/j.annemergmed.2006.09.021. Epub 2006 Nov 13. Ann Emerg Med. 2007. PMID: 17098327 Review.
Cited by
-
Cyanide and Cyanogenic Compounds-Toxicity, Molecular Targets, and Therapeutic Agents.Biomolecules. 2024 Nov 7;14(11):1420. doi: 10.3390/biom14111420. Biomolecules. 2024. PMID: 39595596 Free PMC article. Review.
-
Hydroxocobalamin for the treatment of vasoplegia after lung transplantation: A case series.JHLT Open. 2024 Nov 29;7:100189. doi: 10.1016/j.jhlto.2024.100189. eCollection 2025 Feb. JHLT Open. 2024. PMID: 40144827 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous